This website uses cookies for usage measurement and traffic analysis purposes.
By clicking the "Agree" button or continuing to browse this site, you consent to the use of cookies.
For more details, please refer to the Privacy Policy
(opens in a new window).
I graduated from School of Medicine, The University of Tokyo in 1984, and became a clinical hematologist. Knowing few effective treatments against human cancer, I was deeply engaged in the research for the identification of essential growth-drivers in cancer. I could indeed discover EML4-ALK oncogene when I was a professor at Jichi Medical University, and also find crizotinib-resistant mutations within EML4-ALK and DUX4-IGH oncogene when I was a professor at The University of Tokyo. With these achievements, I was awarded The Medal of Honor with Purple Ribbon from The Japanese Emperor, The Keio Medical Science Prize, The Japan Academy Prize, and The Lépold Griffuel Award (from France). I am also a member of The Japan Academy. In the ATLAS project, I am wishing to support the genomic medicine part.
My expertise is medical genomics and molecular oncology, but my personal goal is to, with the power of science, save the life of as many cancer patients as possible.
| 2021-present | Member of The Japan Academy |
| 2018-present | Director, Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center |
| 2016-present | Director, Research Institute, National Cancer Center |
| 2013-2018 | Professor, Department of Cellular Signaling, Graudate School of Medicine, The University of Tokyo |
| 2001-2013 | Professor, Division of Funtional Genomics, Jichi Medical University |
